-
GeoVax to Present at the Emerging Growth Conference on April 16, 2025
Company to Provide an Update on its GEO-CM04S1 Program, Including the Recent BARDA Contract Termination ATLANTA, GA, April 15, 2025 – GeoVax Labs,…
-
GeoVax to Present Clinical Data at Upcoming April Industry Events
Data to be Presented on the Company’s GEO-CM04S1 and Gedeptin Programs Atlanta, GA, April 15, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology…
-
GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent
Continues to Strengthen its Pandemic Preparedness and Biodefense Vaccine Portfolio ATLANTA, GA, April 9, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology…
-
GeoVax Expands Gedeptin(R) Patent Portfolio
Allowed Patent Claims Cover the Synergistic Combination of Gedeptin® Therapy with Radiation As a Targeted Approach for Solid Tumors Atlanta, GA – May…
-
GeoVax Reports 2024 Year-End Financial Results and Provides Business Update
GEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway and clinical sites confirmed Additional data evaluating GEO-CM04S1…
-
GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
ATLANTA, GA, March 24, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,…
-
GeoVax to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
GeoVax to Host Conference Call at 4:30 PM ET Atlanta, GA, March 17, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology…
-
GeoVax Establishing Strategic Presence in Europe with Initial Footprint in the UK
Hub to Advance Global Vaccine and Immuno-Oncology Development ATLANTA, GA, March 12, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company…
-
GeoVax to Present at the 37th Annual Roth Conference
ATLANTA, GA, March 11, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced…
-
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event “MPOX 2025: Navigating the Global Public Health Emergency” Featuring GeoVax CEO On March 6, 2025
Mpox remains a global public health crisis in 2025, with Clade 1b exhibiting higher transmissibility and severity than Clade 2. The Democratic Republic…
-
GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy
GeoVax’s GEO-MVA: Strengthening U.S. Biodefense ATLANTA, GA – March 3, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a leader in developing vaccines and immunotherapies…
-
GeoVax Response to WHO’s Third Declaration of Mpox as a Public Health Emergency of International Concern
GeoVax Advancing GEO-MVA Vaccine Candidate to Bolster Global Supply Options ATLANTA, GA – February 27, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX) commented on…